Related Experiment Video
Updated: Jul 4, 2025
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Left Atrial Appendage Occlusion and Post-procedural Antithrombotic Management
Anders Kramer1, Giuseppe Patti2,3, Jens Erik Nielsen-Kudsk1
1Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200 Aarhus, Denmark.
Insights
Left atrial appendage occlusion (LAAO) prevents stroke in atrial fibrillation. Post-procedure antithrombotic therapy is crucial for preventing device-related thrombosis (DRT), though optimal regimens remain variable.
Area of Science:
- Cardiology
- Medical Devices
- Thrombosis Research
Background:
- Left atrial appendage occlusion (LAAO) offers an alternative to anticoagulation for stroke prevention in atrial fibrillation.
- Post-procedural antithrombotic therapy is standard to mitigate device-related thrombosis (DRT) risk.
- Current antithrombotic strategies following LAAO exhibit significant international and inter-center variability.
Purpose of the Study:
- To review existing evidence on antithrombotic therapy after LAAO.
- To discuss ongoing randomized trials investigating post-procedural management.
- To explore future directions in managing DRT risk.
Main Methods:
- Literature review of current antithrombotic regimens.
- Analysis of data from clinical studies and animal models.
- Overview of ongoing randomized controlled trials.
Main Results:
- The optimal duration and type of antithrombotic therapy post-LAAO are not definitively established.
- DRT risk is highest within the initial 45-90 days post-implantation.
- Variability in clinical practice highlights the need for standardized guidelines.
Conclusions:
- Evidence-based guidelines for post-LAAO antithrombotic therapy are needed.
- Ongoing trials are critical for defining optimal treatment strategies.
- Future research should focus on personalized antithrombotic approaches to minimize DRT.
Abstract:
Left atrial appendage occlusion (LAAO) is an established alternative to oral anticoagulation for stroke prevention in atrial fibrillation. Antithrombotic therapy is used in the post-procedural period to prevent device-related thrombosis (DRT). The risk of DRT is considered highest in the first 45-90 days after device implantation, based on animal studies of the device healing process. Clinically applied antithrombotic regimens vary greatly across studies, continents, and centers. This article gives an overview of the evidence behind current antithrombotic regimens, ongoing randomized trials, and future post-procedural management.
